Clinical Specialist - Midlands

North America leads Foot and Ankle Reconstruction devices market. Foot and ankle problems don't get the attention that hip and knee replacements do, but the devices used to fix them - plates, screws, fusion systems, total ankle implants - are quietly becoming one of the more dynamic corners of orthopedics. Here's where the market stands and where it's headed. Market Size and Growth Metrics The global foot and ankle reconstruction devices market was valued at USD 1.8 billion in 2025 and is estimated to reach USD 1.9 billion in 2026. From there, it's projected to climb to USD 3.3 billion by 2033, growing at a CAGR of 8.3% between 2026 and 2033 - nearly doubling in under a decade. What's fueling that growth: * An aging population with degenerative joint disease. The CDC estimated roughly 33 million U.S. adults were living with osteoarthritis by the end of 2024, and the Osteoarthritis Action Alliance projects that figure will hit 72 million by 2030 and 78 million by 2040. Around 25% of ankle fractures in patients over 60 are linked to osteoporosis, and ankle osteoarthritis affects an estimated 3.4% of the global adult population - all of which translates into steady surgical demand. * Minimally invasive techniques going mainstream. Surgeons are shifting toward smaller incisions, faster recovery, and procedure-specific instrumentation for tendon repairs, fusions, and osteotomies. * Smarter surgical technology. Computer-assisted navigation, AI-driven imaging interpretation, and predictive planning tools are improving implant placement accuracy and reducing revision rates. By the numbers: * North America led all regions with a 47.9% revenue share in 2025, backed by strong reimbursement systems and high procedure volumes; the U.S. is the largest single country market. * Hallux valgus (bunion) correction was the top application segment at 31.4% share in 2025, though hammertoe correction is expected to grow fastest through the forecast period. * Hospitals captured 59.7% of end-use revenue in 2025, while outpatient/ambulatory surgical centers are the fastest-growing setting, as more elective reconstruction procedures move out of inpatient settings entirely. One notable headwind: regulatory complexity. Compliance with FDA requirements, EU MDR 2017/745, and region-specific approval pathways adds significant time and cost to bringing new implants to market - a burden that falls hardest on smaller manufacturers. Competitive Landscape and Core Players The market splits fairly cleanly into two tiers. Established multinational players - Stryker, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, and Arthrex - compete on scale: broad product portfolios spanning trauma, reconstruction, and sports medicine; deep clinical evidence; global distribution; and long-standing surgeon relationships. Their weakness is largely structural - premium pricing and complex regulatory overhead can limit adoption in cost-sensitive settings. Emerging and specialized players - Globus Medical, Orthofix, Enovis, Acumed, CONMED, and Anika Therapeutics - compete on agility, focusing on procedure-specific fixation systems, orthobiologics, and minimally invasive implants. They move faster on niche innovation but lack the global footprint and hospital procurement relationships of the majors. Recent activity shows both tiers pushing hard on product launches: * Stryker expanded its Foot & Ankle portfolio in the U.S. (September 2024) with the Osteotomy Truss System and Ankle Truss System for fusion and total ankle procedures. * DePuy Synthes launched the TriLEAP Lower Extremity Anatomic Plating System (August 2025) for forefoot and midfoot reconstruction. * Zimmer Biomet and Treace Medical Concepts both showcased updated bunion-correction and total ankle systems at the AOFAS Annual Conference in September 2025. * Fusion Orthopedics acquired Metalogix External Fixation Systems (January 2025), adding external fixation frames and mini-rail systems to its lineup - a sign that M&A activity, while moderate overall, is still reshaping portfolios. Competitive advantage increasingly hinges on demonstrable clinical outcomes and comprehensive, procedure-specific offerings that bundle implants, biologics, and digital surgical planning together, rather than any single device. Product Specifications and Innovation Highlights Reconstruction devices in this market are segmented by the specific anatomical problem they solve. Hallux Valgus/Bunion Correction devices include plates, screws, staples, and intramedullary fixation and osteotomy implants, all designed to realign the first metatarsal and great toe. Hammertoe Correction relies on intramedullary implants, fixation pins, screws, and fusion systems to realign and stabilize the affected interphalangeal joints. Midfoot Reconstruction uses fusion plates, locking screws, and compression staples to stabilize the tarsometatarsal and naviculocuneiform joints following trauma, arthritis, or Charcot foot. Hindfoot & Ankle Reconstruction devices - arthrodesis plates, intramedullary nails, locking screws, and compression systems - restore alignment and stability in severe arthritis, instability, or post-traumatic cases. Total Ankle Replacement (TAR) implants use prosthetic tibial and talar components to replace the damaged joint while preserving natural motion, offering an alternative to fusion for end-stage arthritis. Toe Joint Replacement systems, primarily targeting the first metatarsophalangeal (MTP) joint, use artificial joint implants to restore mobility and relieve pain in arthritic or degenerated toes. Some recent product specifics worth noting: * SINTX Technologies' SINAPTIC Foot & Ankle Osteotomy Wedge System (FDA-cleared October 2025) is made from silicon nitride, engineered specifically for hallux valgus precision. * Medline UNITE's REFLEX HYBRID Nitinol Implant System (FDA 510(k), April 2025) combines locking plate stability with nitinol staple compression for MTP fusions and Lapidus procedures. * Forma Medical's OptimalHT system (2023) brought dedicated minimally invasive instrumentation to hammertoe correction, a segment that had lagged behind bunion surgery in MIS adoption. * NovaBone's bioglass syringes (2.5cc/5cc) target bone defect repair and osseointegration as an adjunct to hardware-based fixation. The throughline across nearly every recent launch is anatomical specificity paired with less invasive delivery - implants engineered for one exact procedure rather than general-purpose hardware, combined with smaller incisions and faster weight-bearing timelines. This market rewards companies that can pair strong clinical data with genuinely differentiated, procedure-specific hardware - a pattern likely to hold as the patient population driving demand (older, more diabetic, more active later in life) continues to grow. Customize This Report - get 20% free customization to tailor scope, segments, or regions to your needs Matched content.

Globus Medical gets Excelsius3D CE mark as European robotics push gains imaging layer. Globus Medical has secured CE marking for its Excelsius3D intraoperative imaging system and can now commercialise the platform across the European Union and United Kingdom, extending its Excelsius ecosystem beyond robotic navigation into integrated imaging as hospitals increasingly evaluate connected surgical technology platforms. September 6, 2026 Globus Medical, Inc. (NYSE: GMED) has received CE marking for its Excelsius3D imaging system, clearing the company to begin commercial sales across the European Union and United Kingdom and giving its robotic surgery strategy another product through which to deepen hospital adoption. Excelsius3D combines 3D cone-beam computed tomography, 2D fluoroscopy and digital radiography in a single mobile platform. The system can operate independently or integrate directly with Globus Medical's ExcelsiusGPS robotic navigation platform, allowing imaging and robotic navigation to function within the same surgical workflow. The system had already received United States Food and Drug Administration 510(k) clearance in 2021, meaning the latest milestone principally expands its commercial geography rather than introducing an entirely new technology. Discover more Pharmaceuticals & Biotech The distinction matters commercially. A hospital buying a standalone imaging system represents one equipment sale, while a hospital that standardises around imaging, navigation and robotics from one vendor can create a broader and potentially stickier technology relationship. Globus Medical is therefore using Excelsius3D not merely as another imaging product but as an additional component in an increasingly interconnected surgical ecosystem. That strategy is being pursued from a sizeable financial base. Globus Medical reported second-quarter 2026 worldwide net sales of $789.6 million, up 5.9% year over year, while GAAP net income reached $151.6 million. Excluding the Nevro business, management said revenue grew around 9%, with United States spine sales increasing 7% and international spine revenue rising 14% as reported. Why does combining three imaging modalities with robotic navigation matter commercially? Discover more Business Operations Business & Industrial business news Operating rooms increasingly contain several expensive technologies that historically have been purchased, installed and operated as separate systems. Surgeons may use fluoroscopy for real-time guidance, 3D imaging to reconstruct anatomy and navigation or robotic systems to plan and execute instrument placement. Excelsius3D attempts to collapse part of that complexity by putting cone-beam CT, fluoroscopy and digital radiography into one mobile system. When connected with ExcelsiusGPS, imaging data can become part of the same procedural environment used for navigation and robotic assistance rather than moving through completely independent workflows. That integration creates an important competitive dimension in musculoskeletal technology. Large medical-device groups increasingly compete not only on implants or individual capital-equipment products but on how much of the procedure they can support through a connected portfolio. Business & Industrial A company supplying implants, imaging, navigation and robotics potentially gains more opportunities to influence hospital purchasing decisions and surgeon workflow. It can also create higher switching costs if users become accustomed to products that share data and are designed to work together. Discover more Business Formation business news Business-News For Globus Medical, the European CE mark therefore has value beyond the immediate number of imaging units it may sell. Every Excelsius3D installation can potentially become another entry point into the wider Excelsius ecosystem. How does the European clearance fit Globus Medical's international growth strategy? International spine was already one of Globus Medical's stronger areas in the second quarter. Management reported 14% year-over-year international spine growth on an as-reported basis and approximately 12% growth at constant currencies. That creates a useful backdrop for Excelsius3D. Engineering & Technology The imaging system can now be marketed in European Union and United Kingdom hospitals where Globus Medical already sells other musculoskeletal products. The company therefore does not need to build a completely new commercial organisation around a single product; it can potentially use existing relationships with surgeons and institutions to expand the technology footprint. Discover more Company Earnings The commercialisation challenge should not be understated, however. CE marking permits market entry but does not create hospital budgets, reimbursement or capital-equipment orders automatically. Hospitals typically evaluate imaging and robotic systems through lengthy purchasing processes that consider clinical utility, utilisation rates, service requirements, operating-room space, staff training and the economics of competing systems. The real milestone will consequently be European installations and utilisation rather than CE marking itself. Could Excelsius3D make Globus Medical's robotic platform more difficult for competitors to displace? That is one of the more interesting strategic implications. Accounting & Auditing A robotic navigation system becomes more valuable if the company supplying it can surround the robot with complementary technology. Globus Medical says Excelsius3D is designed to integrate directly with ExcelsiusGPS, allowing intraoperative images to support robotic navigation. The resulting competitive proposition is different from selling a robot in isolation. Hospitals could theoretically select the imaging system as a standalone product, but a customer already using ExcelsiusGPS has an additional reason to consider Excelsius3D because the systems were designed to operate together. Conversely, an Excelsius3D customer could become a future candidate for robotic navigation. That creates a form of portfolio cross-selling common across mature medical-device markets. The value of each product is partly independent, but the commercial power of the portfolio grows if each installation makes adoption of another product easier. Globus Medical still faces strong competition in spine robotics, imaging and enabling technologies. Medtronic, Johnson & Johnson and other large medical-device businesses are investing heavily in connected surgery, navigation and digital operating-room technologies. The European expansion therefore increases Globus Medical's addressable market but also puts Excelsius3D into a region where hospitals already have multiple sophisticated alternatives. What does Globus Medical's recent share performance say about investor sentiment? The CE mark did not trigger an obvious positive revaluation in Globus Medical shares. The stock closed at $78.12 on September 3, down 3.15% for the session, before finishing September 4 around $78.26. That left the shares roughly 3.8% below their August 31 close of $81.37 and around 4% below the August 4 close of $81.51. The wider valuation range provides useful context. Globus Medical has traded between approximately $54.15 and $101.40 over the past 52 weeks, leaving the latest price well below the upper end of that range despite continuing revenue growth. It would be unsafe to attribute the September 3 decline directly to the Excelsius3D announcement. Regulatory clearances for individual products are only one input into a company with more than $3 billion of trailing revenue and a broad portfolio spanning spine, orthopaedic trauma, joint reconstruction, neuromodulation and enabling technologies. Investor sentiment appears more closely tied to whether Globus Medical can convert its larger post-acquisition portfolio into sustained organic growth and expanding earnings. That makes the European launch useful strategically but unlikely to transform the investment case on its own. What must Globus Medical prove after receiving the Excelsius3D CE mark? Commercial adoption is the next important evidence point. Stocks & Bonds Globus Medical needs European hospitals to purchase Excelsius3D and, ideally, to use the product alongside ExcelsiusGPS in enough procedures to validate the integrated-platform proposition. Installation numbers, capital-equipment sales, international enabling-technology growth and cross-selling into existing accounts will matter more than the regulatory milestone itself. The company also needs to demonstrate that integration produces enough workflow benefit for hospitals to justify purchasing multiple components from the same ecosystem. Capital budgets remain constrained in many healthcare systems, and sophisticated equipment must compete against other clinical priorities. If Excelsius3D strengthens adoption of ExcelsiusGPS as well as generating imaging revenue, the economic impact could exceed the contribution of the imaging platform alone. That is what makes the September clearance strategically interesting. Globus Medical is not entering Europe with an isolated piece of imaging equipment. It is bringing another layer into a surgical platform increasingly designed around imaging, navigation and robotics working together. Discover more from Business-News-Today.com. Accounting & Auditing